MCID: OVR012
MIFTS: 44

Ovarian Serous Cystadenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Serous Cystadenocarcinoma

MalaCards integrated aliases for Ovarian Serous Cystadenocarcinoma:

Name: Ovarian Serous Cystadenocarcinoma 12 52 14 69
Cystadenoma, Serous 69
Serous Cystadenoma 12
Cystadenoma Serous 52

Classifications:



External Ids:

Disease Ontology 12 DOID:5746
NCIt 47 C7978
UMLS 69 C0279663

Summaries for Ovarian Serous Cystadenocarcinoma

Disease Ontology : 12 An ovary serous adenocarcinoma that has material basis in glandular epithelium, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Ovarian Serous Cystadenocarcinoma, also known as cystadenoma, serous, is related to serous cystadenocarcinoma and pancreatic serous cystadenoma. An important gene associated with Ovarian Serous Cystadenocarcinoma is ZNF217 (Zinc Finger Protein 217), and among its related pathways/superpathways are Gene Expression and Apoptosis Modulation and Signaling. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, liver and bone, and related phenotypes are Decreased ionizing radiation sensitivity and cellular

Related Diseases for Ovarian Serous Cystadenocarcinoma

Diseases related to Ovarian Serous Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
id Related Disease Score Top Affiliating Genes
1 serous cystadenocarcinoma 28.3 AKT1 BIRC5 ESR2 PGR VEGFA ZNF217
2 pancreatic serous cystadenoma 12.4
3 cystadenoma 10.8
4 pancreatitis 10.6
5 berk-tabatznik syndrome 10.5 BCL2 PGR
6 cystadenocarcinoma 10.5
7 rheumatic pulmonary valve disease 10.4 UBE4A USP2 ZNF217
8 appendix adenocarcinoma 10.4 UBE4A USP2 ZNF217
9 pulmonary hypertension 10.3 BAX BCL2
10 mature teratoma 10.3 BAX BCL2
11 pediatric meningioma 10.3 BIRC5 PGR
12 congenital hereditary facial paralysis-variable hearing loss syndrome 10.3 BAX BCL2
13 extramedullary plasmacytoma 10.2 BAX ZNF217
14 diffuse lipomatosis 10.2 PGR VEGFA
15 ovarian mesodermal adenosarcoma 10.2 BCL2 BIRC5 PGR
16 metaphyseal dysplasia without hypotrichosis 10.2 BAX BCL2
17 adenosine monophosphate deaminase 1 deficiency 10.2 PGR VEGFA
18 coloboma of superior eyelid 10.1 VEGFA YAP1
19 adenoma 10.1
20 deafness, autosomal dominant 8/12 10.1 ESR2 PGR
21 her2-receptor positive breast cancer 10.1 ESR2 PGR
22 osteogenesis imperfecta 10.0 ESR2 PGR
23 sparse hair ptosis mental retardation 10.0 BCL2 VEGFA
24 microcystic adenoma 9.9
25 obstructive jaundice 9.9
26 adenocarcinoma 9.9
27 perinatal jaundice due to hepatocellular damage 9.9 ESR2 PGR
28 posterior foramen magnum meningioma 9.9 PGR VEGFA
29 primary malignant melanoma of the conjunctiva 9.9 AKT1 VEGFA
30 portal hypertension 9.9
31 endosalpingiosis 9.9
32 struma ovarii 9.9
33 leydig cell tumor 9.9
34 sertoli-leydig cell tumor 9.9
35 tuberculosis 9.9
36 cystadenofibroma 9.9
37 leukemia 9.9
38 endometriosis 9.9
39 plasma cell leukemia 9.9
40 trachea squamous cell carcinoma 9.8 AKT1 PGR VEGFA
41 brown-vialetto-van laere syndrome 9.8 AKT1 PGR VEGFA
42 paroxysmal nocturnal hemoglobinuria 9.8 AKT1 VEGFA YAP1
43 pylorus cancer 9.8 BAX BCL2 VEGFA
44 retinitis pigmentosa 9.8 BAX BCL2 VEGFA
45 breast cancer 9.7
46 obesity 9.7
47 von hippel-lindau syndrome 9.7
48 hepatitis 9.7
49 islet cell tumor 9.7
50 ectopic pregnancy 9.7

Graphical network of the top 20 diseases related to Ovarian Serous Cystadenocarcinoma:



Diseases related to Ovarian Serous Cystadenocarcinoma

Symptoms & Phenotypes for Ovarian Serous Cystadenocarcinoma

GenomeRNAi Phenotypes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased ionizing radiation sensitivity GR00232-A-1 9.1 AKT1 ESR2 PGR UBE4A USP2 YAP1

MGI Mouse Phenotypes related to Ovarian Serous Cystadenocarcinoma:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 AKT1 BAX BCL2 BIRC5 ESR2 FSHR
2 endocrine/exocrine gland MP:0005379 10.21 PGR USP2 VEGFA YAP1 AKT1 BAX
3 behavior/neurological MP:0005386 10.2 AKT1 BAX BCL2 ESR2 FSHR PGR
4 homeostasis/metabolism MP:0005376 10.18 AKT1 BAX BCL2 BIRC5 ESR2 FSHR
5 hematopoietic system MP:0005397 10.15 AKT1 BAX BCL2 BIRC5 ESR2 FSHR
6 cardiovascular system MP:0005385 10.14 ESR2 FSHR PGR USP2 VEGFA YAP1
7 immune system MP:0005387 10.11 AKT1 BAX BCL2 BIRC5 ESR2 FSHR
8 mortality/aging MP:0010768 10.02 ESR2 AKT1 BAX BCL2 BIRC5 FSHR
9 integument MP:0010771 9.98 AKT1 BCL2 ESR2 FSHR PGR VEGFA
10 muscle MP:0005369 9.87 AKT1 BAX BCL2 ESR2 PGR VEGFA
11 neoplasm MP:0002006 9.86 AKT1 BAX BCL2 ESR2 FSHR PGR
12 limbs/digits/tail MP:0005371 9.8 BAX ESR2 FSHR PGR VEGFA
13 renal/urinary system MP:0005367 9.63 BAX BCL2 ESR2 USP2 VEGFA YAP1
14 reproductive system MP:0005389 9.56 VEGFA AKT1 BAX BCL2 ESR2 FSHR
15 respiratory system MP:0005388 9.1 AKT1 BAX BCL2 ESR2 VEGFA YAP1

Drugs & Therapeutics for Ovarian Serous Cystadenocarcinoma

Drugs for Ovarian Serous Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
4
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
5
Doxorubicin Approved, Investigational Phase 2, Phase 3, Phase 1 23214-92-8 31703
6
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
8
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
9
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
10
Trametinib Approved Phase 2, Phase 3 871700-17-3 11707110
11
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
12
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
13
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
14
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
16
Doxil Approved June 1999 Phase 2, Phase 3, Phase 1 31703
17
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
18
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
19
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
20 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
21 Antimitotic Agents Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
23 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
24 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
25 Antibodies Phase 3,Phase 2,Phase 1
26 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
27 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
28 Immunoglobulins Phase 3,Phase 2,Phase 1
29 Mitogens Phase 3,Phase 2,Phase 1
30 Anti-Bacterial Agents Phase 2, Phase 3, Phase 1
31 Antibiotics, Antitubercular Phase 2, Phase 3, Phase 1
32 Protein Kinase Inhibitors Phase 2, Phase 3, Phase 1
33 topoisomerase I inhibitors Phase 2, Phase 3, Phase 1
34 Topoisomerase Inhibitors Phase 2, Phase 3, Phase 1
35 Anti-Infective Agents Phase 3,Phase 2,Phase 1
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
37 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
38 Alkylating Agents Phase 3,Phase 2,Phase 1
39 Antirheumatic Agents Phase 3,Phase 2,Phase 1
40 Anticoagulants Phase 2, Phase 3
41 Antineoplastic Agents, Hormonal Phase 2, Phase 3
42 Aromatase Inhibitors Phase 2, Phase 3
43 Bone Density Conservation Agents Phase 2, Phase 3
44 Calcium, Dietary Phase 2, Phase 3
45 Chelating Agents Phase 2, Phase 3
46 Estrogen Antagonists Phase 2, Phase 3
47 Estrogen Receptor Modulators Phase 2, Phase 3
48 Estrogens Phase 2, Phase 3
49 Hormone Antagonists Phase 2, Phase 3
50 Hormones Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 93)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
2 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
4 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
5 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
8 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
9 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
10 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
11 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
12 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
13 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
14 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
15 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
16 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
17 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
18 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
19 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
20 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
21 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
22 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
23 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
24 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00022347 Phase 2 canfosfamide hydrochloride
25 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
26 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride
27 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers Completed NCT00002538 Phase 2
28 Phase II ABT-888 With Cyclophosphamide Completed NCT01306032 Phase 2 ABT-888;Cyclophosphamide
29 Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer Completed NCT01583322 Phase 2 vargatef;placebo
30 AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Completed NCT00275028 Phase 2 cediranib maleate
31 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
32 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2 Gemcitabine Hydrochloride;WEE1 Inhibitor AZD1775
33 Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02122185 Phase 2 paclitaxel;carboplatin;docetaxel;metformin hydrochloride;placebo
34 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02853318 Phase 2 Cyclophosphamide
35 Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation Recruiting NCT02953457 Phase 1, Phase 2 Olaparib
36 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
37 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
38 Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02627443 Phase 1, Phase 2 ATR Kinase Inhibitor VX-970;Carboplatin;Gemcitabine Hydrochloride
39 MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
40 Selumetinib in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Active, not recruiting NCT00551070 Phase 2 selumetinib
41 Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Active, not recruiting NCT02283658 Phase 2 Everolimus;Letrozole
42 VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT01666444 Phase 2 pegylated liposomal doxorubicin (PLD);VTX-2337;Placebo
43 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
44 Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02345265 Phase 2 Cediranib Maleate;Olaparib
45 Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting NCT01116648 Phase 1, Phase 2 Cediranib Maleate;Olaparib
46 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Terminated NCT00004221 Phase 2 Carboplatin;Cyclophosphamide;Paclitaxel;Topotecan Hydrochloride
47 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Terminated NCT00331422 Phase 2 carboplatin;paclitaxel
48 Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer Terminated NCT00354601 Phase 2 capecitabine;docetaxel
49 Toremifene in Treating Patients With Ovarian Cancer Withdrawn NCT00003865 Phase 2 toremifene
50 Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Completed NCT01459380 Phase 1 Carboplatin;Pegylated Liposomal Doxorubicin Hydrochloride;Veliparib

Search NIH Clinical Center for Ovarian Serous Cystadenocarcinoma

Genetic Tests for Ovarian Serous Cystadenocarcinoma

Anatomical Context for Ovarian Serous Cystadenocarcinoma

MalaCards organs/tissues related to Ovarian Serous Cystadenocarcinoma:

39
Ovary, Liver, Bone, Endothelial, Brain, Bone Marrow

Publications for Ovarian Serous Cystadenocarcinoma

Articles related to Ovarian Serous Cystadenocarcinoma:

(show all 19)
id Title Authors Year
1
Expression of Yes-associated proteinA 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
2
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
3
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
4
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
5
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
6
Ovarian serous cystadenocarcinoma metastasising to the breast. ( 23445161 )
2013
7
Nanog is highly expressed in ovarian serous cystadenocarcinoma and correlated with clinical stage and pathological grade. ( 21266826 )
2010
8
Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. ( 18574502 )
2008
9
Plasma cell leukemia with ovarian serous cystadenocarcinoma. ( 17883177 )
2007
10
[Differential expression of USP2, USP14 and UBE4A between ovarian serous cystadenocarcinoma and adjacent normal tissues]. ( 17553343 )
2007
11
[ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. ( 17160949 )
2006
12
[Oncogene ZNF217 amplification on chromosome 20 q in ovarian serous cystadenocarcinoma and its clinical implications]. ( 16793610 )
2006
13
Hormone replacement therapy after invasive ovarian serous cystadenocarcinoma treatment: the effect on survival. ( 11201519 )
2001
14
Immunohistochemical localization of aromatase and apoptosis-associated proteins in ovarian serous cystadenocarcinoma arising from ovarian endometriosis. ( 11516810 )
2001
15
Successful treatment of an advanced ovarian serous cystadenocarcinoma in pregnancy with cisplatin, adriamycin and cyclophosphamide (CAP) regimen. Case report. ( 10968352 )
2000
16
Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. ( 9506768 )
1998
17
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen. ( 2314830 )
1990
18
Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). ( 3165255 )
1988
19
Characterization of newly established cell line HUOA from a human ovarian serous cystadenocarcinoma. ( 3598277 )
1987

Variations for Ovarian Serous Cystadenocarcinoma

ClinVar genetic disease variations for Ovarian Serous Cystadenocarcinoma:

6 (show all 45)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
3 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
4 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
5 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
6 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
7 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
8 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
9 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
10 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
11 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
12 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
13 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
14 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
15 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
16 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
17 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
18 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
19 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
20 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
21 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
22 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
23 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
24 TP53 NM_000546.5(TP53): c.580C> T (p.Leu194Phe) single nucleotide variant Pathogenic/Likely pathogenic rs587780071 GRCh37 Chromosome 17, 7578269: 7578269
25 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
26 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
27 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
28 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
29 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
30 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
31 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
32 TP53 NM_000546.5(TP53): c.856G> A (p.Glu286Lys) single nucleotide variant Pathogenic/Likely pathogenic rs786201059 GRCh37 Chromosome 17, 7577082: 7577082
33 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
34 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
35 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
36 TP53 NM_000546.5(TP53): c.833C> T (p.Pro278Leu) single nucleotide variant Pathogenic/Likely pathogenic rs876659802 GRCh37 Chromosome 17, 7577105: 7577105
37 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
38 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
39 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh38 Chromosome 1, 114713907: 114713907
40 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
41 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
42 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic/Likely pathogenic rs730882005 GRCh37 Chromosome 17, 7577568: 7577568
43 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic/Likely pathogenic rs1057519981 GRCh37 Chromosome 17, 7577569: 7577569
44 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
45 TP53 NM_000546.5(TP53): c.700T> C (p.Tyr234His) single nucleotide variant Pathogenic/Likely pathogenic rs864622237 GRCh37 Chromosome 17, 7577581: 7577581

Expression for Ovarian Serous Cystadenocarcinoma

Search GEO for disease gene expression data for Ovarian Serous Cystadenocarcinoma.

Pathways for Ovarian Serous Cystadenocarcinoma

Pathways related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 43)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.65 AKT1 BAX BIRC5 ESR2 PGR USP2
2
Show member pathways
12.69 AKT1 BAX BCL2 BIRC5
3
Show member pathways
12.67 AKT1 BAX BCL2 VEGFA
4 12.53 AKT1 BAX BCL2 BIRC5 VEGFA
5
Show member pathways
12.39 AKT1 BAX BCL2 BIRC5 YAP1
6
Show member pathways
12.35 AKT1 BAX BCL2 ESR2
7
Show member pathways
12.14 AKT1 BAX BCL2
8 12.12 BAX BCL2 BIRC5
9 12.11 AKT1 BAX BCL2
10 12.08 AKT1 BAX BIRC5 VEGFA
11
Show member pathways
12.05 AKT1 BAX BCL2 BIRC5 ESR2 PGR
12 12.01 AKT1 BAX BCL2 VEGFA
13 11.97 AKT1 BCL2 VEGFA
14
Show member pathways
11.92 AKT1 BAX BCL2
15
Show member pathways
11.91 AKT1 BAX BCL2
16 11.91 AKT1 BAX BCL2 USP2
17 11.89 AKT1 BAX BCL2
18 11.87 AKT1 BAX BCL2
19 11.8 AKT1 BCL2 VEGFA
20 11.76 AKT1 BCL2 BIRC5 VEGFA
21 11.72 AKT1 BAX BCL2
22
Show member pathways
11.71 BAX BCL2 BIRC5
23 11.55 AKT1 BAX BCL2 VEGFA
24 11.48 AKT1 BIRC5 VEGFA
25 11.42 AKT1 BAX BCL2
26 11.4 AKT1 BAX BCL2
27 11.39 AKT1 BCL2 BIRC5
28 11.33 AKT1 BCL2 BIRC5
29 11.25 BAX BIRC5 VEGFA
30 11.18 AKT1 BIRC5
31 11.18 ESR2 FSHR PGR
32 11.12 AKT1 BAX BCL2 BIRC5
33 11.11 AKT1 FSHR
34 11.08 AKT1 ESR2
35 11.06 BAX BCL2 ESR2
36 11.05 AKT1 VEGFA
37 11.02 AKT1 BCL2
38
Show member pathways
11 BAX BCL2
39 10.93 BAX BCL2
40 10.91 AKT1 BAX BCL2
42 10.62 BAX BCL2
43 10.43 AKT1 BAX BCL2 YAP1

GO Terms for Ovarian Serous Cystadenocarcinoma

Cellular components related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.96 AKT1 BAX BCL2 BIRC5 ESR2 PGR
2 nucleoplasm GO:0005654 9.56 AKT1 BCL2 BIRC5 ESR2 PGR USP2
3 mitochondrial outer membrane GO:0005741 9.33 BAX BCL2 PGR
4 pore complex GO:0046930 8.62 BAX BCL2

Biological processes related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.92 AKT1 BCL2 BIRC5 VEGFA
2 cellular response to DNA damage stimulus GO:0006974 9.91 AKT1 BAX BCL2 YAP1
3 cell proliferation GO:0008283 9.86 AKT1 BAX BCL2 YAP1
4 positive regulation of cell proliferation GO:0008284 9.81 BCL2 BIRC5 VEGFA
5 transcription initiation from RNA polymerase II promoter GO:0006367 9.79 ESR2 PGR YAP1
6 negative regulation of neuron apoptotic process GO:0043524 9.74 BAX BCL2 BIRC5
7 male gonad development GO:0008584 9.71 BAX BCL2 FSHR
8 cellular response to hypoxia GO:0071456 9.7 AKT1 BCL2 VEGFA
9 kidney development GO:0001822 9.69 BAX BCL2 VEGFA
10 regulation of apoptotic process GO:0042981 9.65 BAX BCL2 BIRC5
11 regulation of mitochondrial membrane potential GO:0051881 9.64 BAX BCL2
12 homeostasis of number of cells within a tissue GO:0048873 9.63 BAX BCL2
13 positive regulation of blood vessel endothelial cell migration GO:0043536 9.61 AKT1 VEGFA
14 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.61 AKT1 BCL2 VEGFA
15 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.6 AKT1 VEGFA
16 release of cytochrome c from mitochondria GO:0001836 9.59 BAX BCL2
17 B cell homeostasis GO:0001782 9.58 BAX BCL2
18 negative regulation of apoptotic signaling pathway GO:2001234 9.58 BAX BCL2
19 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.55 BAX BCL2
20 growth GO:0040007 9.49 BCL2 VEGFA
21 regulation of protein heterodimerization activity GO:0043497 9.46 BAX BCL2
22 ovarian follicle development GO:0001541 9.43 BAX BCL2 VEGFA
23 regulation of protein homodimerization activity GO:0043496 9.4 BAX BCL2
24 Sertoli cell proliferation GO:0060011 9.37 BAX FSHR
25 leukocyte homeostasis GO:0001776 9.32 BAX BCL2
26 regulation of nitrogen utilization GO:0006808 9.16 BAX BCL2
27 positive regulation of developmental pigmentation GO:0048087 8.96 BAX BCL2
28 apoptotic mitochondrial changes GO:0008637 8.8 AKT1 BAX BCL2

Molecular functions related to Ovarian Serous Cystadenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 AKT1 BAX BCL2 BIRC5 ESR2 FSHR
2 protein heterodimerization activity GO:0046982 9.73 BAX BCL2 VEGFA YAP1
3 enzyme binding GO:0019899 9.62 AKT1 BIRC5 ESR2 PGR
4 steroid binding GO:0005496 9.4 ESR2 PGR
5 protein phosphatase 2A binding GO:0051721 9.37 AKT1 BCL2
6 channel activity GO:0015267 9.26 BAX BCL2
7 identical protein binding GO:0042802 9.1 AKT1 BAX BCL2 BIRC5 USP2 VEGFA
8 BH3 domain binding GO:0051434 8.96 BAX BCL2

Sources for Ovarian Serous Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....